Latest news & press releases prev  -  next

FLT3 programme licensing opportunity

Sentinel Oncology is pleased to announce that its FLT3 kinase programme is available for partnering.

Mutations in the FLT3 gene are amongst the most frequent genetic defects found in acute myeloid leukemia (AML). Sentinel Oncology has developed a novel lead series of small molecule drugs which act as potent inhibitors of FLT3 and represent an excellent opportunity to develop pre-clinical candidate drugs... read more

For more information about the Sentinel Oncology p70S6 kinase programme, visit our website at or contact us to arrange a collaborative discussion.

March 30, 2010



Sentinel Oncology will be at the following events this year


18th - 22nd April 2015

AACR - Philadelphia


29th May - 2nd June 2015

ASCO - Chicago


15th - 18th June 2015

BIO - Philadelphia


5th - 9th November 2015